The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Modulation of the antitumor immune response by complement
Open accessAbstract
The involvement of complement-activation products in promoting tumor growth has not yet been recognized. Here we show that the generation of complement C5a in a tumor microenvironment enhanced tumor growth by suppressing the antitumor CD8+ T cell–mediated response. This suppression was associated with the recruitment of myeloid-derived suppressor cells into tumors and augmentation of their T cell–directed suppressive abilities. Amplification of the suppressive capacity of myeloid-derived suppressor cells by C5a occurred through regulation of the production of reactive oxygen and nitrogen species. Pharmacological blockade of the C5a receptor considerably impaired tumor growth to a degree similar to the effect produced by the anticancer drug paclitaxel. Thus, our study demonstrates a therapeutic function for complement inhibition in the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
The complement system in regulation of adaptive immunity
Carroll, M. C. (2004) · Nature Immunology · doi:10.1038/ni1113 · Cited by 1,035
ROLE OF C5A IN INFLAMMATORY RESPONSES
Guo, R.-F., & Ward, P. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115835 · Cited by 1,021
Lin, K. Y., Guarnieri, F., Staveley-O’Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., & Wu, T. ‐. (1996) · PubMed · Cited by 1,003
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Self-citationKusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight
Markiewski, M. M., & Lambris, J. D. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070166 · Cited by 722
Self-citationPerforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., MacGregor, D., Godfrey, D. I., & Trapani, J. A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.755 · Cited by 576
Tumour immunity: effector response to tumour and role of the microenvironment
Mantovani, A., Romero, P., Palucka, A. K., & Marincola, F. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60241-x · Cited by 537
Sahu, A., & Lambris, J. D. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800103.x · Cited by 525
Self-citationWessels, M. R., Butko, P., Ma, M., Warren, H. B., Lage, A. L., & Carroll, M. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11490 · Cited by 503
Complement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
Self-citationMollnes, T. E., Brekke, O., Fung, M. S. C., Fure, H., Christiansen, D., Bergseth, G., Videm, V., Lappegård, K. T., Köhl, J., & Lambris, J. D. (2002) · PubMed · doi:10.1182/blood.v100.5.1869.h81702001869_1869_1877 · Cited by 455
Self-citationConejo-Garcia, J. R., Benencia, F., Courreges, M.-C., Kang, E., Mohamed-Hadley, A., Buckanovich, R. J., Holtz, D. O., Jenkins, A., Na, H., Zhang, L., et al. (2004) · Nature Medicine · doi:10.1038/nm1097 · Cited by 437
Self-citationThe proinflammatory mediators C3a and C5a are essential for liver regeneration
Strey, C. W., Markiewski, M., Mastellos, D., Tudoran, R., Spruce, L. A., Greenbaum, L. E., & Lambris, J. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030374 · Cited by 436
Self-citationFunction, structure and therapeutic potential of complement C5a receptors
Monk, P. N., Scola, A., Madala, P., & Fairlie, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707332 · Cited by 404
Fishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 400
Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma
Karp, C. L., Grupe, A., Schadt, E., Ewart, S. L., Keane-Moore, M., Cuomo, P. J., Köhl, J., Wahl, L., Kuperman, D., Germer, S., et al. (2000) · Nature Immunology · doi:10.1038/79759 · Cited by 378
The C5a chemoattractant receptor mediates mucosal defence to infection
Höpken, U. E., Lu, B., Gerard, N. P., & Gerard, C. (1996) · Nature · doi:10.1038/383086a0 · Cited by 344
Self-citationTumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells
Kusmartsev, S., Nagaraj, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4583 · Cited by 310
Complement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo
Liu, J., Miwa, T., Hilliard, B., Chen, Y., Lambris, J. D., Wells, A. D., & Song, W.-C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20040863 · Cited by 252
Self-citationLow-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a
Finch, A. M., Wong, A. K., Paczkowski, N. J., Wadi, S. K., Craik, D. J., Fairlie, D. P., & Taylor, S. M. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806594 · Cited by 246
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma
Kohl, J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26582 · Cited by 217
Abrogation of the alternative complement pathway by targeted deletion of murine factor B
Matsumoto, M., Fukuda, W., Circolo, A., Goellner, J., Strauss-Schoenberger, J., Wang, X., Fujita, S., Hidvegi, T., Chaplin, D. D., & Colten, H. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8720 · Cited by 215
Immune evasion of tumor cells using membrane-bound complement regulatory proteins
Gorter, A., & Meri, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01537-6 · Cited by 206
Markiewski, M. M., Mastellos, D., Tudoran, R., DeAngelis, R. A., Strey, C. W., Franchini, S., Wetsel, R. A., Erdei, A., & Lambris, J. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.747 · Cited by 170
Self-citationComplement and Toll-like receptors: Key regulators of adaptive immune responses
Hawlisch, H., & Köhl, J. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.06.028 · Cited by 168
Circolo, A., Garnier, G., Fukuda, W., Wang, X., Hidvegi, T., Szalai, A. J., Briles, D. E., Volanakis, J. E., Wetsel, R. A., & Colten, H. R. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00021-1 · Cited by 166
Complement: more than a ‘guard’ against invading pathogens?
Mastellos, D. C., & Lambris, J. D. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02287-1 · Cited by 157
Self-citationPersistent complement activation on tumor cells in breast cancer.
Niculescu, F. I., Rus, H., Retegan, M., et al. (1992) · PubMed · Cited by 144
Donin, N., Jurianz, K., Ziporen, L., Schultz, S., Kirschfink, M., & Fishelson, Z. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02066.x · Cited by 139
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 136
Benencia, F., Courreges, M. C., Conejo-Garcia, J. R., Mohamed-Hadley, A. A., Zhang, L., Buckanovich, R. J., Carroll, R. H., Fraser, N. W., & Coukos, G. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.026 · Cited by 127
Self-citationSuresh, M., Molina, H. D., Salvato, M. S., Mastellos, D. C., Lambris, J. D., & Sándor, M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.788 · Cited by 120
Self-citationComplement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses
Kim, A. H. J., Dimitriou, I. D., Holland, M. C., Mastellos, D. C., Mueller, Y. M., Altman, J. D., Lambris, J. D., & Katsikis, P. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2524 · Cited by 106
Self-citationNeutrophil C5a receptor and the outcome in a rat model of sepsis
Guo, R., Riedemann, N. C., Bernacki, K. D., Sarma, V. J., Laudes, I. J., Reuben, J. S., Younkin, E. M., Neff, T. A., Paulauskis, J. D., Zetoune, F. S., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0009fje · Cited by 84
Drug evaluation: the C5a receptor antagonist PMX-53.
Köhl, J. (2006) · PubMed · Cited by 80
Cancer's Bulwark Against Immune Attack: MDS Cells
Marx, J. L. (2008) · Science · doi:10.1126/science.319.5860.154 · Cited by 77
Johswich, K. O., Martin, M., Thalmann, J., Rheinheimer, C., Monk, P. N., & Klos, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m609734200 · Cited by 67
Peng, T., Hao, L., Madri, J. A., Su, X., Elias, J. A., Stahl, G. L., Squinto, S. P., & Wang, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22906 · Cited by 62
Mastellos, D. C. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2003.10.019 · Cited by 62
Synthetic small-molecule complement inhibitors.
Holland, M. C., Morikis, D., & Lambris, J. D. (2004) · PubMed · Cited by 53
Self-citationEarly Neoplastic Progression Is Complement Independent
de Visser, K. E., Korets, L. V., & Coussens, L. M. (2004) · Neoplasia · doi:10.1593/neo.04250 · Cited by 47
Complement regulates inhalation tolerance at the dendritic cell/T cell interface
Köhl, J., & Wills-Karp, M. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.06.016 · Cited by 46
Daniel, D., Dai, G., Singh, C. R., Lindsey, D. R., Smith, A. K., Dhandayuthapani, S., Hunter, R. L., & Jagannath, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4688 · Cited by 38
Structure, functions, and evolution of the third complement component and viral molecular mimicry
Sahu, A., Sunyer, J. O., Moore, W. T., Sarrias, M., Soulika, A. M., & Lambris, J. D. (1998) · Immunologic Research · doi:10.1007/bf02786436 · Cited by 30
Self-citationHoltz, D. O., Krafty, R. T., Mohamed-Hadley, A. A., Zhang, L., Alagkiozidis, I., Leiby, B. E., Guo, W., Gimotty, P. A., & Coukos, G. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-2 · Cited by 24
Self-citation
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
“Unexpectedly, the dogma that complement protects against tumors was further challenged when a recent study showed that classical pathway-induced generation of C5a in the tumor microenvironment leads to significant progression in tumor growth in a mouse model of cervical cance”
BackgroundSelf-citationMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Metadata
- Authors
- Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D.
- Venue
- Nature Immunology
- Published
- 2008-09-28
- Volume
- 9
- Issue
- 11
- Pages
- 1225-1235
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2076936113
- Cited by
- 778
- References
- 58
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.